JPMorgan lowered the firm’s price target on Ardent Health (ARDT) to $15 from $18 and keeps a Neutral rating on the shares. The firm updated the company’s model post the Q2 report.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARDT:
- Ardent Health price target lowered to $23 from $24 at Leerink
- Ardent Health price target lowered to $20 from $24 at KeyBanc
- Sell Rating for Ardent Health Partners Due to Anticipated State Directed Payment Cuts and Profitability Challenges
- Ardent Health Reports Strong Q2 2025 Results
- Ardent Health reports Q2 EPS 52c, consensus 32c